Fox Chase’s Y. Lynn Wang Presents Research at Hematology Meeting That Could Help Predict Effectiveness of Cancer Drug
PHILADELPHIA (December 14, 2021)—Loss of the protein-tyrosine phosphatase SHP1 may be used as a biomarker to predict efficacy of ibrutinib in certain cases of diffuse large B-cell lymphoma (DLBCL), according to the results of a study by Fox Chase Cancer Center researchers presented in a poster at the 63rd ASH Annual Meeting and Exposition.